Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Core Insights - Palisade Bio, Inc. has been selected to present data on its lead program PALI-2108 for ulcerative colitis at Digestive Disease Week (DDW) 2025, indicating recognition of its research within the gastroenterology field [1][2] - The company focuses on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, aiming to transform treatment landscapes through targeted approaches [3] Presentation Details - PALI-2108 will be featured in two poster presentations at DDW 2025, with the first session on May 4, 2025, discussing a bioinformatic approach revealing potential anti-fibrotic efficacy [2] - The second presentation on May 5, 2025, will highlight PALI-2108's bioactivation in the colon and its effects on colon tissue PDE4B, increasing c-AMP and suppressing TNF-α in a mouse model of colitis [2] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company dedicated to advancing therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases [3]